| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16af92ee77e743c1a480090acac98204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a39570c8c0d69b5486fef835f7e1c45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b61f8c3638a2853e3adf0e432bf5b8fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2007-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_787daa40103b7d6dc3fd900d9a4c8ad4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8fe5419a403b5fe55c23fd2e68dbf86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5e5a8e55a9a0a9b3b75361458ffd15 |
| publicationDate |
2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9428582-B2 |
| titleOfInvention |
Method of treating rash in patients undergoing anti-EGFR therapy |
| abstract |
The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10583111-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10967197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10987336-B2 |
| priorityDate |
2006-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |